Antonio Vita1, Luca De Peri2, Giacomo Deste3, Stefano Barlati3, Emilio Sacchetti4. 1. University of Brescia, School of Medicine; Department of Mental Health, Spedali Civili Hospital, Brescia, Italy. Electronic address: vita@med.unibs.it. 2. University of Brescia, School of Medicine. 3. Department of Mental Health, Spedali Civili Hospital, Brescia, Italy. 4. University of Brescia, School of Medicine; Department of Mental Health, Spedali Civili Hospital, Brescia, Italy.
Abstract
BACKGROUND: Deficits in cortical gray matter (GM) have been found in patients with schizophrenia, with evidence of progression over time. The aim of this study was to determine the role of potential moderators of such changes, in particular of the amount and type of antipsychotic medication intake. METHODS: Longitudinal magnetic resonance imaging studies comparing changes in the volume of cortical GM over time between patients with schizophrenia and healthy control subjects published between January 1, 1983, and March 31, 2014, were analyzed. Hedges' g was calculated for each study and volume changes from baseline to follow-up were analyzed. Meta-regression statistics were applied to investigate the role of potential moderators of the effect sizes. RESULTS: Eighteen studies involving 1155 patients with schizophrenia and 911 healthy control subjects were included. Over time, patients with schizophrenia showed a significantly higher loss of total cortical GM volume. This was related to cumulative antipsychotic intake during the interval between scans in the whole study sample. Subgroup meta-analyses of studies on patients treated with second-generation antipsychotics and first-generation antipsychotics revealed a different and contrasting moderating role of medication intake on cortical GM changes: more progressive GM loss correlated with higher mean daily antipsychotic intake in patients treated with at least one first-generation antipsychotic and less progressive GM loss with higher mean daily antipsychotic intake in patients treated only with second-generation antipsychotics. CONCLUSIONS: These findings add useful information to the controversial debate on the brain structural effects of antipsychotic medication and may have both clinical relevance and theoretical implications.
BACKGROUND: Deficits in cortical gray matter (GM) have been found in patients with schizophrenia, with evidence of progression over time. The aim of this study was to determine the role of potential moderators of such changes, in particular of the amount and type of antipsychotic medication intake. METHODS: Longitudinal magnetic resonance imaging studies comparing changes in the volume of cortical GM over time between patients with schizophrenia and healthy control subjects published between January 1, 1983, and March 31, 2014, were analyzed. Hedges' g was calculated for each study and volume changes from baseline to follow-up were analyzed. Meta-regression statistics were applied to investigate the role of potential moderators of the effect sizes. RESULTS: Eighteen studies involving 1155 patients with schizophrenia and 911 healthy control subjects were included. Over time, patients with schizophrenia showed a significantly higher loss of total cortical GM volume. This was related to cumulative antipsychotic intake during the interval between scans in the whole study sample. Subgroup meta-analyses of studies on patients treated with second-generation antipsychotics and first-generation antipsychotics revealed a different and contrasting moderating role of medication intake on cortical GM changes: more progressive GM loss correlated with higher mean daily antipsychotic intake in patients treated with at least one first-generation antipsychotic and less progressive GM loss with higher mean daily antipsychotic intake in patients treated only with second-generation antipsychotics. CONCLUSIONS: These findings add useful information to the controversial debate on the brain structural effects of antipsychotic medication and may have both clinical relevance and theoretical implications.
Authors: Hila Abush; Subroto Ghose; Erin A Van Enkevort; Brett A Clementz; Godfrey D Pearlson; John A Sweeney; Matcheri S Keshavan; Carol A Tamminga; Elena I Ivleva Journal: Psychiatry Res Neuroimaging Date: 2018-03-28 Impact factor: 2.376
Authors: Kalina Christoff; Zachary C Irving; Kieran C R Fox; R Nathan Spreng; Jessica R Andrews-Hanna Journal: Nat Rev Neurosci Date: 2016-09-22 Impact factor: 34.870
Authors: Ganesh B Chand; Dominic B Dwyer; Guray Erus; Aristeidis Sotiras; Erdem Varol; Dhivya Srinivasan; Jimit Doshi; Raymond Pomponio; Alessandro Pigoni; Paola Dazzan; Rene S Kahn; Hugo G Schnack; Marcus V Zanetti; Eva Meisenzahl; Geraldo F Busatto; Benedicto Crespo-Facorro; Christos Pantelis; Stephen J Wood; Chuanjun Zhuo; Russell T Shinohara; Haochang Shou; Yong Fan; Ruben C Gur; Raquel E Gur; Theodore D Satterthwaite; Nikolaos Koutsouleris; Daniel H Wolf; Christos Davatzikos Journal: Brain Date: 2020-03-01 Impact factor: 13.501